Tianjin Chase Sun Pharmaceutical Co.,Ltd (SHE:300026)
2.900
-0.070 (-2.36%)
Nov 20, 2026, 3:04 PM CST
SHE:300026 Revenue
Tianjin Chase Sun Pharmaceutical Co.,Ltd had revenue of 918.33M CNY in the quarter ending September 30, 2026, a decrease of -32.16%. This brings the company's total for the last twelve months to 3.90B, down -28.99% year-over-year. In the year 2025, Tianjin Chase Sun Pharmaceutical Co.,Ltd had annual revenue of 4.94B, down -14.55%. That makes Tianjin Chase Sun Pharmaceutical Co.,Ltd the 10,406th largest company in the world by revenue and 1,695th in China.
Revenue (ttm)
3.90B
Revenue Growth
-28.99%
P/S Ratio
2.23
Revenue / Employee
803.55K
Employees
4,852
Market Cap
8.71B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full SHE:300026 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.94B | -841.64M | -14.55% |
| Dec 31, 2024 | 5.78B | -326.09M | -5.34% |
| Dec 31, 2023 | 6.11B | -541.17M | -8.14% |
| Jan 1, 2023 | 6.65B | -1.02B | -13.30% |
| Dec 31, 2021 | 7.67B | 1.18B | 18.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Zhejiang Medicine | 8.43B |
| Zhejiang CONBA Pharmaceutical | 6.83B |
| Zhejiang Jingxin Pharmaceutical | 4.06B |
| Zhejiang Xianju Pharmaceutical | 3.86B |
| Yantai Dongcheng Pharmaceutical Group | 2.63B |
| PharmaBlock Sciences (Nanjing) | 2.19B |
| Zhejiang Hisoar Pharmaceutical | 2.03B |
| Shenzhen Chipscreen Biosciences | 1.08B |